INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines

Pomerantz LLP filed a securities class action against Regeneron (REGN) over alleged securities fraud/unlawful practices tied to its Phase 3 Fianlimab-Libtayo trial disclosures. Shares dropped $45.41 (-6.21%) on April 29, 2026 after the study was altered, and then fell $68.57 (-9.82%) on May 16, 2026 after the trial failed to reach statistical significance for the primary progression-free survival endpoint. The lawsuit and these disclosures reinforce downside risk around the company’s clinical/data credibility and outlook.

Analysis

This is less about the lawsuit itself than about a credibility reset for REGN’s pipeline valuation. When a late-stage oncology program misses a clean endpoint after protocol changes, investors typically re-rate the entire development stack, not just the failed asset, because the market starts discounting management’s probability-weighting and design choices. That matters most for a company whose multiple already embeds a premium for durable innovation beyond the core commercial franchise.

Second-order effects favor incumbents with approved immuno-oncology combinations and cleaner catalysts. BMY’s Opdualag and MRK’s broader oncology basket can capture any share of mind lost by REGN in the LAG-3/PD-1 space, while smaller immuno-oncology names may also get scrutinized on trial design and endpoint robustness. The legal overhang itself is usually a slow-burn issue, but it can extend the de-rating if analysts pull forward legal expense, management distraction, or a more conservative stance on disclosure risk.

The key distinction is time horizon: the stock can stabilize quickly if investors decide this is a one-program miss, but the next 1-3 months are vulnerable to estimate cuts and conference-season questions on pipeline breadth. Over 6-18 months, the thesis is either a normalization trade if core commercial growth remains intact, or a structural multiple compression if the market decides the pipeline is less scalable than previously implied. What would falsify the bearish view is a credible update showing faster advancement of the next late-stage asset or evidence that the core franchise can re-accelerate without incremental R&D spend.

Key Decisions for Investors

• Short REGN into any post-news bounce; target a 1-3 month window where analyst model cuts and governance discount can still expand, with risk anchored to management reaffirming pipeline value at the next update.
• Pair trade: long BMY / short REGN for 1-3 months to express relative immuno-oncology substitution; BMY benefits if capital rotates toward approved combo exposure while REGN absorbs pipeline skepticism.
• If holding REGN, consider buying downside protection via 3-6 month puts rather than selling outright; the event risk is less about immediate litigation loss and more about a slower multiple reset from credibility damage.
• Watch for catalyst-driven re-rating: any guidance cut to R&D productivity, additional trial-design scrutiny, or downward revisions to peak sales assumptions would extend the bearish case; absent that, cover shorts on stabilization after the next earnings call.